Top

Gepubliceerd in:

2015 | OriginalPaper | Hoofdstuk

Preventie en behandeling van aandoeningen als gevolg van atherosclerose

Auteur : Prof. dr. A. F. H. Stalenhoef

Uitgeverij: Bohn Stafleu van Loghum

Abstract

Preventie en behandeling van aandoeningen die het gevolg zijn van atherosclerose liggen in elkaars verlengde: het onderscheid tussen primaire en secundaire preventie van cardiovasculaire aandoeningen is door voortschrijdend inzicht in de vaatwandbiologie en pathogenese van atherosclerose kunstmatig gebleken. Een 50-jarige man met een combinatie van risicofactoren zoals diabetes, hypertensie en roken en zonder manifest vaatlijden kan een hoger risico hebben op het krijgen van een myocardinfarct in de komende tien jaar dan een man met een oud onderwandinfarct zonder deze risicofactoren. Beiden vallen wel in de hoogrisicocategorie.

Multidisciplinaire richtlijn Cardiovasculair risicomanagement 2006. Van Zuyden Communication B.V. ISBN-10 :90-8523-131-0 (www.cbo.nl/richtlijnen/folder20021023121843).

Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). Graham I et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J. 2007 Oct;28(19):2375–414.PubMedCrossRef

CAPRIE steering committee. A randomized blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329–39.

Cholesterolverlagende therapie. Den Haag: Gezondheidsraad, 2000; publicatienr. 2000/17.

Mokdad AH, Bowman BA, Ford ES, et al. The continuing epidemics of obesity and diabetes in the United States. JAMA 2001;286:1195–2000.PubMedCrossRef

Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383–9.

Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20.536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002;360:7–22.CrossRef

The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984;251:351–64CrossRef

The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984;251:365–74.CrossRef

10.

Buchwald H, Varco RL, Matts JP, et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med 1990;323:946–55.PubMedCrossRef

11.

Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHATLLT). JAMA 2002;288:2998–3007.

12.

Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOTLLA): a multicentre randomised controlled trial. Lancet 2003;361:1149–58.PubMedCrossRef

13.

Shepherd J, Cobbe SM, Ford I, et al., for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301–7.PubMedCrossRef

14.

Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001–9.PubMedCrossRef

15.

Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349–57.CrossRef

16.

Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615–22.PubMedCrossRef

17.

Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383–93.PubMedCrossRef

18.

Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357:2109–22.PubMedCrossRef

Titel: Preventie en behandeling van aandoeningen als gevolg van atherosclerose
Auteur: Prof. dr. A. F. H. Stalenhoef
Uitgeverij: Bohn Stafleu van Loghum
DOI: https://doi.org/10.1007/978-90-313-6597-5_4

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Abstract

Log in om toegang te krijgen